Compare VCTR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCTR | ADMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | 2018 | 2012 |
| Metric | VCTR | ADMA |
|---|---|---|
| Price | $67.63 | $9.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $73.30 | $32.00 |
| AVG Volume (30 Days) | 866.4K | ★ 7.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.08 | 0.60 |
| Revenue | ★ $413,412,000.00 | $42,219,783.00 |
| Revenue This Year | $18.90 | $27.46 |
| Revenue Next Year | $6.25 | $22.11 |
| P/E Ratio | $17.05 | ★ $13.82 |
| Revenue Growth | 0.92 | ★ 43.85 |
| 52 Week Low | $47.00 | $7.21 |
| 52 Week High | $77.78 | $25.67 |
| Indicator | VCTR | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 26.88 |
| Support Level | $65.27 | N/A |
| Resistance Level | $72.38 | $16.44 |
| Average True Range (ATR) | 1.74 | 1.11 |
| MACD | 0.15 | -0.68 |
| Stochastic Oscillator | 32.10 | 26.59 |
Victory Capital Holdings Inc is a diversified investment management firm. The company provides specialized investment strategies to institutions, intermediaries, retirement platforms and individual investors. Its offerings include actively and passively managed mutual funds, rules-based and active exchange traded funds (ETFs), institutional separate accounts, variable insurance products (VIPs), alternative investments, private closed end funds, and a 529 Education Savings Plan. The company operates in one operating and reportable segment that provides investment management services and products to institutional, intermediary, retirement platforms and individual investors. The majority of the company's revenue consists of Investment management fees.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.